雷贝拉唑三联疗法治疗幽门螺杆菌阳性十二指肠溃疡

目的观察雷贝拉唑三联短程疗法治疗幽门螺杆菌(H.pylori)阳性十二指肠溃疡的疗效.方法100例经胃镜检查确诊为十二指肠溃疡并经快速尿素酶实验和病理学检查确定为H.pylori阳性的患者随机分为两组雷贝拉唑组和奥美拉唑组.两组先予以三联疗法雷贝拉唑10mg或奥美拉唑20mg、阿莫西林1g及克拉霉素500mg,每日2次,连续7天,然后给予雷贝拉唑10mg或奥美拉唑20mg,每天1次,连续7天,疗程结束后4周复查胃镜并检测H.pylori,并记录用药后患者症状的改变程度.结果93例完成治疗方案.其中雷贝拉唑组2周溃疡愈合率为93.6%,奥美拉唑组为73.9%,雷贝拉唑组明显高于奥美拉唑组,两组有显著性差异(P＜0.05),雷贝拉唑组第1、3天症状缓解率分别为68.1%、91.4%,奥美拉唑组为39.1%、65.2%,两组比较差异有显著性(P＜0.05);雷贝拉唑H.pylori根除率为91.5%,奥美拉唑组为86.9%,两组间无显著性差异(P＞0.05).结论雷贝拉唑、克拉霉素和阿莫西林三联短程疗法能有效根除H.pylori及提高溃疡愈合率,并能迅速缓解症状,与奥美拉唑三联疗法相比较,在H.pylori根除率上无显著性差异,而在2周溃疡愈合率及症状缓解率方面,雷贝拉唑却明显优于奥美拉唑.     

止溃汤与雷尼替丁治疗十二指肠溃疡疗效对比观察

经胃镜确诊的60例十二指肠球部溃疡患者，随机分为止溃疡治疗组和雷尼替丁对照组，治疗4周末进行胃镜复查，结果表明止溃汤组和雷尼替丁组，4周愈合率分别为87.2%和92.9%。两组的溃疡愈合率和疼痛缓解率均无显著性差异，未出现严重的副作用。因此认为止溃汤是治疗十二指肠溃疡较为理想的方剂。     

奥美拉唑和克拉霉素及阿莫西林三联疗法治疗肝源性溃疡疗效观察

目的观察奥美拉唑、克拉霉素、阿莫西林三联疗法治疗肝源性溃疡的疗效。方法经胃镜确诊的肝源性溃疡患者58例,随机分为治疗组(31例)和对照组(27例)。两组患者均给予综合治疗。治疗组患者给予奥美拉唑20mg,口服,2次/d;克拉霉素500mg,口服,2次/d;阿莫西林1000mg,口服,2次/d。对照组单用奥美拉唑20mg,口服,2次/d。十二指肠溃疡治疗2周,胃溃疡治疗3周。疗程结束后,用内窥镜观察溃疡愈合情况。结果治疗组和对照组溃疡愈合率分别为87.0%和55.5%,差异有统计学意义(P<0.01);治疗后6个月和12个月,治疗组溃疡复发率分别为14.8%和18.5%,对照组分别为33.3%和40.0%,差异均有统计学意义(P<0.01)。结论奥美拉唑、克拉霉素、阿莫西林三联疗法治疗肝源性溃疡临床效果显著。     

潘托拉唑治疗消化性溃疡临床疗效观察

目的：研究潘托拉唑治疗消化性溃疡的疗效及安全性。方法：将经胃镜证实的消化性溃疡患者随机分成潘托拉唑组（治疗组,简称潘组）和奥美拉唑组（对照组,简称奥组）,其中潘组60例,应用潘托拉唑40mg,1次／d;奥组58例;应用败类美拉唑20mg,1次／d。十二指肠溃疡患者疗程4周,胃溃疡6周。停药后均复查胃镜观察溃疡愈合情况。治疗期间每周随访1次。并记录症状改善情况及不良反应。结果：十二指肠溃疡的愈合率两组分别为91．7％和94．7％,胃溃疡的愈合率两组分别为91．7％反应。结果十二指肠溃疡的愈合率两组分别为91．7％和94．7％,胃溃疡的愈合率两组分别为91．7％和90．0％,P值均＞0．05。各项症状的改善情况两组相仿（P＞0．05）。治疗期间,两组均有良好的耐受性。结论潘托拉唑对消化性溃疡有较高的治愈率和症状改善率。疗效与奥美拉唑相当,其不良反应很少,患者耐受性好,是一种有应用前景的质子泵抑制剂。     

洛赛克与泰胃美治疗消化性溃疡对比观察

材料与方法:将内镜确诊的活动性消化性溃疡(PU)随机分为洛赛克(L)组46例,泰胃美(T)组40例,两组患者的性别,年龄、病程、溃疡平均面积及吸烟史等均具有可比性。L组给予洛赛克20mg,每日1次,睡前服,疗程2～4周;T组给予泰胃美800mg,每晚1次、疗程同上。治疗过程中不加用其他抗溃疡药物。治疗2周、4周后各复查胃镜1次,了解溃疡的愈合情况。 结果:L组28例DU服药2周愈合23例,4周愈合27例;18例GU2周愈合11例,4周愈合15例。     

止溃汤与雷尼替丁治疗十二指肠溃疡疗效对比观察

经胃镜确诊的６０例十二指肠球部溃疡患者，随机分为止溃疡治疗组和雷尼替丁对照组，治疗４周末进行胃镜复查，结果表明止溃汤组和雷尼替丁组，４周愈合率分别为８７．２％和９２．９％。两组的溃疡愈合率和疼痛缓解率均无显著性差异，未出现严重的副作用。因此认为止溃汤是治疗十二指肠溃疡较为理想的方剂。     

三九胃泰四联疗法治疗消化性溃疡及根除幽门螺杆菌的临床研究

目的 为探讨三九胃泰对消化性溃疡的治疗作用和根除幽门螺杆菌的效果，南方医院和北京医科大学第一附属医院同时进行随机对照临床研究。方法 132例消化性溃疡病人随机分为三组，治疗组(A组)三九胃泰2．5g 雷尼替丁150mg 阿莫西林500mg 甲硝唑400mg，bid；对照组1(B组)铋剂220mg 雷尼替丁150mg 阿莫西林500mg 甲硝唑400mg，bid；对照组2(C组)雷尼替丁150mg 阿莫西林500mg 甲硝唑400mg，bid。以上药物服2周后停用抗生素，余药服满6周疗程结束，第7周复查胃镜和(或)呼气试验。其中A组78例，B组3l例，C组23例。结果 三组病人症状缓解率相似，A、B、C组溃疡愈合率分为85．1％，83．9％，82．6％(无显著差异)，溃疡S2期获得率分别为64．0％、61．5％或43．5％，(A、B组均高于C组)。Hp根除率分别为74．2％、73．3和52．6％。三组均无明显副反应发生。结论 雷尼替丁三联疗法加用三九胃泰治疗消化性溃疡，可使S期获得率增加。同时幽门螺杆菌根除率上升，其效果与加用铋剂效果相近，临床观察无明显副作用。     

雷贝拉唑与奥美拉唑三联疗法治疗幽门螺杆菌阳性消化性溃疡的疗效比较

目的比较雷贝拉唑与奥美拉唑三联疗法治疗幽门螺杆菌（HP）阳性消化性溃疡的疗效。方法将经胃镜检查确认为Hp阳性的活动性消化性溃疡患者74例,随机方法分为两组。治疗组37例,口服雷贝拉唑10mg,阿莫西林1000mg及克拉霉素500mg,2次／d,治疗1周后继续单独口服雷贝拉唑10mg,2次／d;对照组37例,口服奥美拉唑20mg,阿莫西林1000mg及克拉霉素500mg,2次／d,治疗1周后继续单独口服奥美拉唑20mg,2次／d。两组十二指肠球部溃疡疗程为4周,胃溃疡为6周。用药结束4周后复查胃镜并检测Hp。结果治疗组和对照组用药1d的临床症状缓解率分别为81％和57％,差异有统计学意义（P〈0．05）;7d后症状缓解率分别为97％和92％,差异无统计学意义（P〉0．05）。溃疡愈合率分别为92％和76％,差异有统计学意义（P〈0．05）;治疗溃疡总有效率分别为97％和92％,差异无统计学意义（P〉0．05）。Hp根除率分别为89％和84％,差异无统计学意义（P〉0．05）。结论两组均能有效缓解消化性溃疡的临床症状和促进溃疡愈合及根除Hp,但雷贝拉唑三联疗法在改善临床症状及促进溃疡愈合方面优于奥美拉唑三联疗法。     

拉萨地区藏药治疗消化性溃疡50例

目的探讨藏药治疗消化性溃疡的临床疗效.方法拉萨地区消化性溃疡患者100例,随机分为藏、西药两组,每组各50人.治疗4wk后复查胃镜及Hp.结果本次研究得出治疗组、对照组溃疡的愈合率分别为57%、61%,两组间总体愈合率接近,愈合率及愈合质量对比差异均无显著性(P=0.176,P＞0.05);治疗组球部溃疡、胃溃疡的愈合率分别为48%、81%,对照组球部溃疡、胃溃疡的愈合率分别为86%、36%,两组比较χ2=16.75,(P＜0.001).治疗组、对照组Hp清除率分别为15%、69%,(χ2=25.02,P＜0.001).结论本地区藏、西药治疗消化性溃疡的愈合率接近,藏药治疗消化性溃疡的临床疗效确切.     

康复新液联合兰索拉唑治疗非甾体抗炎药相关性溃疡38例

[目的]探讨康复新联合兰索拉唑治疗非甾体抗炎药（NSIADs）相关性溃疡的疗效。[方法]将经胃镜确诊的76例NSAIDs相关性溃疡患者,随机分为2组,治疗组38例,应用康复新10 ml,3次/d,兰索拉唑30 mg,1次/d;对照组38例,应用兰索拉唑30 mg,1次/d,疗程均为4周。疗程结束后,记录症状转归,胃镜复查评估溃疡愈合情况。[结果]2组临床症状改善情况比较差异无统计学意义（P〉0.05）。溃疡的愈合率和总有效率治疗组为94.7%和97.4%,对照组为78.9%和84.2%,2组比较差异有统计学意义（P〈0.05）。[结论]康复新联合兰索拉唑治疗NSIADs相关性溃疡可提高溃疡的愈合率和总有效率。     

Role of anti-secretory treatment in addition to Helicobacter pylori eradication triple therapy in the treatment of peptic ulcer]

BACKGROUND/AIMS: It is not clear whether the anti-secretory therapy should be continued for symptomatic relief and ulcer healing before or after the eradication of H. pylori in patients with peptic ulcer disease. The aim of this study was to evaluate the effectiveness of additional anti-secretory therapy before or after H. pylori eradication in peptic ulcer disease. METHODS: Thirty eight patients with H. pylori-positive active peptic ulcer were included. Patients were randomly allocated into 3 groups; standard 1-week triple therapy followed by omeprazole (20 mg, qd) for 3 weeks (group A), standard 1-week triple therapy only (group B), and omeprazole (20 mg, qd) for 3 weeks followed by 1-week triple therapy (group C). Endoscopy with the rapid urease test and histology for H. pylori was performed 4-8 weeks after the completion of treatment. The symptom was scored by a visual analog scale. RESULTS: Of the 38 patients, 10 were excluded from the per-protocol analysis of this study. The H. pylori eradication rates were 87.5% (group A), 80.0% (group B) and 90.0% (group C) respectively. The peptic ulcer healing rates were 100% in group A, 70.0% in group B, and 90.0% in group C. There was no difference in H. pylori eradication rates and ulcer healing rates among three groups (p>0.05). Symptom score differences between pre-treatment and post-treatment group were not significantly different (p>0.05). CONCLUSIONS: The standard one week triple therapy with or without 3-weeks anti-secretory treatment with omeprazole before or after the therapy does not affect H. pylori eradication rates, peptic ulcer healing rates, and symptom score improvement.     

茶色素治疗消化性溃疡临床疗效观察

目的评估茶色素治疗消化性溃疡的临床疗效.方法100例经胃镜诊断的消化性溃疡患者,随机分成两组,每组50例,采用双盲对照观察.治疗组茶色素250mg,2次/日;对照组雷尼替丁150mg,2次/日.4周后胃镜复查.结果100例消化性溃疡患者,失访5例(治疗组3例,对照组2例),95例完成治疗和胃镜复查.根据意图治疗分析(ITT),治疗组治愈率为80%(42/50),对照组治愈率为88%(44/50).两组治愈率经统计学处理无显著差异(P＞0.5).对照组出现4例AST轻度升高,治疗组未见副作用发生.结论茶色素治疗消化性溃疡有良好的效果.     

艾普拉唑肠溶片治疗十二指肠溃疡的多中心、随机、双盲、阳性平行对照临床研究

目的 初步评价艾普拉唑肠溶片治疗十二指肠溃疡的疗效和安全性,探讨剂量-疗效关系.方法 采用多中心、随机、双盲双模拟、阳性药物平行对照设计.将胃镜检查证实为活动性十二指肠溃疡患者235例随机分为艾普拉唑低(5 mg/d)、中(10 mg/d)、高(20 mg/d)剂量组和奥美拉唑组(20 mg/d),各组连续服药4周.观察治疗后溃疡愈合及临床症状的改善情况.结果 不同剂量艾普拉唑和奥美拉唑均可快速缓解患者腹痛、烧灼感、反酸、恶心呕吐、嗳气、腹胀等临床症状,4周末综合症状改善显效率和有效率、单一症状改善有效率在各组间差异均无统计学意义(P值均>0.05).2周和4周溃疡愈合率在艾普拉唑低剂量组分别为72.88%和86.44%,中剂量组分别为86.21%和93.10%,高剂量组分别为76.27%和86.44%,奥美拉唑组分别为72.88%和89.83%,各组间差异无统计学意义(P>0.05).不良反应主要为腹泻、微量蛋白尿、头痛、头晕、转氨酶升高等,四组均未发生严重不良反应.结论 三种剂量艾普拉唑肠溶片均能快速缓解十二指肠溃疡患者的临床症状,促进溃疡愈合,且安全有效,但疗效与剂量无明显相关性.     

拉呋替丁片治疗十二指肠溃疡的多中心、随机、双盲、双模拟对照研究

目的观察拉呋替丁片治疗十二指肠溃疡的安全性和有效性。方法采用多中心、随机、双盲、双模拟对照设计。按入选标准将入选患者随机分为拉呋替丁组（111例）和法莫替丁组（109例）两组。拉呋替丁组给予拉呋替丁片10 mg,每天2次;法莫替丁组给予法莫替丁片20 mg每天2次。连续服用4周。观察治疗后溃疡愈合及临床症状的缓解情况。结果法莫替丁组痊愈率为35.78%,拉呋替丁组为51.35%。法莫替丁组愈合率为77.98%,拉呋替丁组为79.28%。法莫替丁组临床有效率为94.50%,拉呋替丁组为91.89%。两组患者总体疗效、愈合率及临床有效率比较均无显著性差异（P〉0.05）,但拉呋替丁组痊愈率明显高于法莫替丁组（P〈0.05）。两组均未发生严重不良反应。结论拉呋替丁用于治疗十二指肠溃疡可有效促进溃疡愈合,改善患者临床症状,效果与法莫替丁相近。     

根除幽门螺杆菌三联疗法临床观察

目的　观察以质子泵抑制剂 (PPI)、克拉霉素为中心的三联疗法治疗幽门螺杆菌 (HP)阳性十二指肠溃疡的疗效 ,比较甲硝唑和痢特灵的疗效及副作用 ,筛选理想的三联疗法。方法　胃镜确诊十二指肠溃疡并经病理组织学及 14 C-尿素呼吸试验证实 HP感染者 184例 ,随机分成 2组 ,A组用洛塞克、克拉霉素及甲硝唑 ,B组用洛塞克、克拉霉素及痢特灵 ,每日 2次 ,连续 7d,停药 4周后复查胃镜观察溃疡愈合程度 ,同时经 14 C-尿素呼吸试验及胃镜证实 HP根除情况。结果　溃疡总愈合率 :A组 91.4 % (85 / 93) ,B组 93.4 % (85 / 91) ,2种疗法比较差异无显著意义 (P >0 .0 5 ) ;HP根除率 :A组 90 .3% (84 / 93) ,B组 93.4 % (85 / 91) ,2种疗法比较差异无显著意义 (P >0 .0 5 ) ;轻度不良反应 :A组 16 .1% (15 / 93) ,B组 4 .4 % (4/ 91) ,B组反应明显轻于 A组 (P <0 .0 5 )。结论　 2组三联疗法根除 HP及治疗十二指肠溃疡均有良好疗效 ;痢特灵具有抗 HP作用强、无耐药性、价格低廉、副作用少等优点 ,可替代甲硝唑配伍于洛塞克、克拉霉素的三联疗法中 ,是一种理想的适合国情的根除 HP方案     

Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile?

AIMS: To compare the efficacy of one-week versus two-week treatment with lansoprazole, amoxycillin and clarithromycin in inducing healing of Helicobacter pylori-positive duodenal ulcers as well as to investigate the role of several factors, determinant in the ulcer healing process. PATIENTS AND METHODS: Seventy-one active duodenal ulcer patients were randomised to receive one- or two-week treatment with lansoprazole (30 mg bid), clarithromycin (500 mg bid) and amoxycillin (1 g bid), not followed by any additional acid suppressive therapy. Ulcer healing and Helicobacter pylori infection were assessed by endoscopy and urea breath test 4 weeks after the end of treatment. Before entering the trial and four weeks after the end of treatment, dyspeptic symptoms were recorded and scored by a validated questionnaire. The potential effects of a number of clinical variables on the ulcer healing process were evaluated by means of univariate and multivariate analyses. RESULTS: Duodenal ulcer was healed in 80.5% patients treated for one week and in 91.4% patients treated for 2 weeks according to intention-to-treat analysis (p=NS). Ulcer healing was more frequent in the Helicobacter pylori cured patients compared to those with persisting infection (90.9% vs 68.5%; p=0.04). Multivariate analysis did not reveal any significant predictor of duodenal ulcer healing. CONCLUSIONS: Two-week treatment with lansoprazole, amoxycillin and clarithromycin, without continuation of antisecretive therapy, is better, although the difference is not statistically significant, than one-week treatment in healing Helicobacter pylori-positive duodenal ulcer disease. The eradication of Helicobacter pylori is the most important factor related to ulcer healing.     

Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.

The purpose of this study was to compare duodenal ulcer healing, symptom relief, and safety of lansoprazole (a new proton pump inhibitor) given at doses of 30 mg and 60 mg, in the morning with ranitidine 300 mg at bedtime. Two hundred and eighty nine patients were enrolled over a 20 month period in a double blind randomised parallel group comparative study set in outpatient endoscopy units of six United Kingdom medical centres. Patients were randomised to receive lansoprazole 30 mg in the morning (n = 95), 60 mg in the morning (n = 96), or ranitidine 300 mg at bedtime (n = 98) for four weeks. Efficacy was assessed by gastroscopy at study entry and after two and four weeks of treatment. Symptom relief was monitored by patient diaries and physician review at two and four weeks. Both doses of lansoprazole resulted in significantly greater ulcer healing than ranitidine after two and four weeks. Respective healing rates on lansoprazole 30 mg, 60 mg, and ranitidine 300 mg were 78%, 80%, and 60% after two weeks and 93%, 97%, and 81% after four weeks. Patients on lansoprazole 30 mg (p = 0.002) and lansoprazole 60 mg (p = 0.026) also recorded greater relief of night time pain in the diary cards during the first seven days of treatment than those on ranitidine. Patients on lansoprazole 60 mg reported significantly better pain relief at their two week visit compared with those receiving ranitidine (p = 0.007). There were no differences between treatment groups in the occurrence or pattern of adverse drug reactions during the trial. It is concluded that for patients with duodenal ulcer, lansoprazole 30 mg or 60 mg is associated with faster ulcer healing and better symptom relief than ranitidine 300 mg at bedtime. There were no significant differences between lansoprazole 30 mg and 60 mg. These data indicate that lansoprazole should be used at a once daily dose of 30 mg for the treatment of duodenal ulcer.     

Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases

AIM: Rabeprazole has been known to inhibit H(+)/K(+)-ATPase more rapidly than omeprazole, the prototype proton pump inhibitor (PPI). The aim of this study was to demonstrate equivalence between low-dose rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of active peptic ulcer and for improvement of symptoms. Also, the effect of CYP2C19 genotypes on ulcer healing rapidity was investigated. METHODS: A total of 112 patients with active peptic ulcer were randomized to receive either rabeprazole 10 mg q.d. or omeprazole 20 mg q.d. for 6 weeks. The remaining ratios (%) and complete healing of the ulcer were determined by endoscopy at 1 week and 6 weeks of treatment. The severity of ulcer pain was also investigated during treatment. CYP2C19 genotype was determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. RESULTS: The remaining ratio of peptic ulcers after 1 week and the complete healing rate after 6 weeks in the rabeprazole versus omeprazole group were 45.5% versus 50.3% (P = 0.475) and 80.6% versus 87.0% (P = 0.423), respectively. CYP2C19 genotypes had no effect on the remaining ratio of peptic ulcers after 1 week and the healing rate of peptic ulcers after 6 weeks in both groups. The proportions of patients with symptom improvement or resolution were comparable between the two groups. CONCLUSION: Low-dose rabeprazole 10 mg has a similar efficacy for the healing rapidity of active peptic ulcer disease and symptom improvement compared with standard-dose omeprazole 20 mg.     

康复新液联合潘托拉唑治疗消化性溃疡疗效分析

目的研究康复新液与潘托拉唑联合治疗消化性溃疡（PU）的疗效。方法将经胃镜检查确诊的128例PU患者随机分为两组,治疗组65例,口服康复新液10ml每日3次,潘托拉唑40mg每日1次口服;对照组63例,口服潘托拉唑40mg每日1次。治疗期间每周1次随防,记录症状转归情况。疗程结束后,胃镜复查评估溃疡愈合情况。结果各项临床症状的改善和疼痛消失情况两组相比差异无显著性（P〉0.05）。PU的愈合率和总有效率治疗组为95.4%和98.5%。对照组为82.5%和87.3%,两组相比差异有显著性（P〈0.05）。两组在用药期间,不良反应少,均有良好的耐受性。结论康复新液联合潘托拉唑治疗PU可提高溃疡的愈合率和总有效率,缩短溃疡的愈合时间。